NCT01427738View on ClinicalTrials.gov

Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis

PHASE3CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

January 31, 2014

Conditions
HIV-1 Infection
Interventions
DRUG

Gentian Violet

Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.

DRUG

Nystatin oral suspension

Participants were administered Nystatin oral suspension 4 times a day for 14 days.

Trial Locations (10)

20200

Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho

30100

AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret

411001

BJ Medical College CRS (31441), Pune

411026

National AIDS Research Institute Pune CRS (11601), Pune

Unknown

Gaborone Prevention/Treatment Trials CRS (12701), Gaborone

Molepolole Prevention/Treatment Trials CRS (12702), Molepolole

College of Med. JHU CRS (30301), Blantyre

Joint Clinical Research Centre (JCRC) (12401), Kampala

UZ-Parirenyatwa CRS (30313), Harare

4013 SF

Durban Adult HIV CRS (11201), Durban

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT01427738 - Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis | Biotech Hunter | Biotech Hunter